There are reports that the much-anticipated results of the two companies' personalized melanoma vaccines have been released, and the treatment results have fallen short of expectations, and Moderna and MSD's stock prices have declined accordingly. The two companies announced in August that this customized vaccine in combination with MSD's best-selling drug Keytruda has achieved “significant and clinically significant” results in reducing the recurrence of this fatal tumor. Moderna's stock price had soared sharply when the news was announced, but no specific data was disclosed at the time. The detailed results are due to be officially announced at the European Society of Medical Oncology's annual meeting in Madrid this Saturday. On Thursday, details about the vaccine began leaking from unverified sources on social platforms, and Moderna and MSD shares declined as a result. One of the accounts published a report signed by Oncology Central, which stated that the risk of recurrence or death was reduced by 42%. However, this figure falls short of the benchmark in investors' memories. An earlier study involving different patient groups and time periods showed that the joint program reduced the risk of recurrence or death by 49% and reduced the risk of distant metastasis or death by 59%. The leak value of 42% is significantly lower than 49%, while key indicators such as the full risk ratio, confidence interval, and event count of the Phase III trial have not been disclosed. In the absence of official data, the market chose to price at a “known lower figure.”
Zhitongcaijing · 3d ago
Share
Listen to the news
There are reports that the much-anticipated results of the two companies' personalized melanoma vaccines have been released, and the treatment results have fallen short of expectations, and Moderna and MSD's stock prices have declined accordingly. The two companies announced in August that this customized vaccine in combination with MSD's best-selling drug Keytruda has achieved “significant and clinically significant” results in reducing the recurrence of this fatal tumor. Moderna's stock price had soared sharply when the news was announced, but no specific data was disclosed at the time. The detailed results are due to be officially announced at the European Society of Medical Oncology's annual meeting in Madrid this Saturday. On Thursday, details about the vaccine began leaking from unverified sources on social platforms, and Moderna and MSD shares declined as a result. One of the accounts published a report signed by Oncology Central, which stated that the risk of recurrence or death was reduced by 42%. However, this figure falls short of the benchmark in investors' memories. An earlier study involving different patient groups and time periods showed that the joint program reduced the risk of recurrence or death by 49% and reduced the risk of distant metastasis or death by 59%. The leak value of 42% is significantly lower than 49%, while key indicators such as the full risk ratio, confidence interval, and event count of the Phase III trial have not been disclosed. In the absence of official data, the market chose to price at a “known lower figure.”
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending